{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-000432","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.714960+00:00","generated_at":"2026-05-16T11:40:17.997001+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MetaVia reports positive Phase 1b results for DA-1726; 9.1% weight loss by Day 54","bullets":["Statistically significant 9.1% weight loss (21.2 lbs) and 9.8 cm waist reduction by Day 54 in Phase 1b MAD cohort.","Liver stiffness reduced 23.7% by Day 54 via VCTE, indicating direct hepatic effect.","Fasted glucose improved 12.3 mg/dL from baseline of 105.3 mg/dL; prediabetic subject HbA1c dropped from 6.0% to 5.5%.","No treatment-related discontinuations; GI events mild to moderate.","Plans 16-week titration studies to 48 mg and 64 mg; results expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-000432","json":"https://secwatch.observer/filing/0001104659-26-000432.json","markdown":"https://secwatch.observer/filing/0001104659-26-000432.md","text":"https://secwatch.observer/filing/0001104659-26-000432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926000432/0001104659-26-000432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926000432/tm2528002d7_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:40:17.997001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}